Blog
RSS FeedPosted by Michael Wonder on 06 Nov 2019
Octapharma’s fibryga receives European label extension to treat acquired fibrinogen deficiency (AFD)
5 November 2019 - Octapharma announced today that the human fibrinogen concentrate fibryga has received approval for use in treatment of ...
Posted by Michael Wonder on 05 Nov 2019
A severe shortage hits a drug used for cancer, immune disorders, epilepsy, causing canceled treatments and rationing
5 November 2019 - A severe shortage of immune globulin — a popular medicine used to treat epilepsy, cancer and ...
Posted by Michael Wonder on 08 Oct 2019
FDA approves Octapharma’s Wilate for haemophilia A in adult and adolescent patients
8 October 2019 - Octapharma USA today announced the U.S. FDA has approved Wilate for treatment of adults and adolescents with ...
Posted by Michael Wonder on 29 Jul 2019
Platelet rich plasma treatment is not classified as a drug, Health Canada says
27 July 2019 - Agency clarifies its position on controversial treatment made popular by superstar athletes. ...
Posted by Michael Wonder on 13 Jul 2019
Esperoct is now approved in Canada for the treatment of haemophilia A in both children and adults
12 July 2019 - New treatment can help Canadians living with haemophilia A better manage their bleeding episodes ...
Posted by Michael Wonder on 08 Jul 2019
ADMA Biologics receives FDA approval for license transfers for Bivigam and Nabi-HB
8 July 2019 - All aspects of the Biotest Therapy Business Unit acquisition are successfully completed. ...
Posted by Michael Wonder on 04 Jul 2019
Grifols announces FDA approval of Xembify, 20% subcutaneous immunoglobulin for primary immunodeficiencies
4 July 2019 - Xembify is Grifols’ first 20% subcutaneous immunoglobulin for the treatment of primary immunodeficiencies. ...
Posted by Michael Wonder on 21 Jun 2019
Esperoct (turoctocog alfa pegol, N8-GP) approved in the EU
20 June 2019 - Novo Nordisk today announced that the European Commission has granted marketing authorisation for Esperoct for the treatment ...
Posted by Michael Wonder on 12 May 2019
FDA approves prior approval supplement for Bivigam
10 May 2019 - ADMA Biologics announces that the U.S. FDA has approved the Company’s prior approval supplement for Bivigam (immune ...
Posted by Michael Wonder on 01 May 2019
PHARMAC fully funding innovative improvements in haemophilia treatment
30 April 2019 - PHARMAC has today provided haemophilia patients fully funded access to new innovative treatment options which will ...
Posted by Michael Wonder on 03 Apr 2019
FDA approves Asceniv, a novel intravenous immune globulin
1 April 2019 - Approved for use in the treatment of primary humoral immunodeficiency disease in adults and adolescents (12 to ...
Posted by Michael Wonder on 08 Mar 2019
Decision to make changes to funded haemophilia treatments
8 March 2019 - PHARMAC is pleased to announce changes to funded haemophilia treatments that will result in two new ...
Posted by Michael Wonder on 20 Feb 2019
Novo Nordisk receives US FDA approval of Esperoct (turoctocog alfa pegol, N8-GP)
19 February 2019 - Novo Nordisk today announced that the US FDA has approved the biologics license application for Esperoct ...
Posted by Michael Wonder on 29 Jan 2019
Proposal for changes to funded haemophilia treatments
29 January 2019 - PHARMAC is proposing to make changes to the funding of haemophilia treatments from 1 May 2019, ...
Posted by Michael Wonder on 07 Jan 2019
ADMA Biologics submits response and provides supplemental information to FDA for Bivigam complete response letter
7 January 2019 - ADMA Biologics announces that the Company has submitted responses to the U.S. FDA complete response letter received ...